Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors With or Without Chemotherapy
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY
The purpose of the study is to find some biomarkers to predict the the adverse events of Immune Checkpoint Inhibitors monotherapy or plus platinum based chemotherapy in lung cancer.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Understand the requirements and contents of the clinical trial, and provide a signed and dated informed consent form.
• Age ≥ 18 years.
• Histologically or cytologically confirmed lung cancer.
• Treated with Immune Checkpoint Inhibitors with or without chemotherapy.
⁃ 6\. Predicted survival ≥ 12 weeks. 7. Adequate bone marrow hematopoiesis and organ function 8. Presence of measurable lesions according to RECIST 1.1.
Locations
Other Locations
China
Hunan Cancer Hospital
RECRUITING
Changsha
Contact Information
Primary
Yongchang Zhang, MD
zhangyongchang@csu.edu.cn
+8613873123436
Backup
Nong Yang, MD
yangnong0217@163.com
+8613873123436
Time Frame
Start Date: 2021-10-01
Estimated Completion Date: 2027-09-14
Participants
Target number of participants: 12000
Treatments
Experimental: Cohort A: Chemotherapy plus Immune Checkpoint Inhibitors
Lung Cancer patients treated with Chemotherapy plus Immune Checkpoint Inhibitors.
Experimental: Cohort B: Immune Checkpoint Inhibitors monotherapy
Lung Cancer patients treated with Immune Checkpoint Inhibitors monotherapy.
Experimental: Cohort C: Chemotherapy Group.
Lung Cancer patients treated with Chemotherapy.
Related Therapeutic Areas
Sponsors
Leads: Hunan Province Tumor Hospital